The Searle Company Limited Collaborates with Mabwell Pharmaceuticals to Manufacture and Market Denosumab Biosimilars in Pakistan

Karachi, The Searle Company Limited, a leading pharmaceutical company in Pakistan, has recently entered into a License Agreement with Mabwell Pharmaceuticals, China. Under this agreement, The Searle Company Limited will undertake the manufacturing, registration, and marketing of Denosumab Biosimilars drugs in Pakistan. This strategic partnership aims to bring high-quality and affordable biological medicines to patients in the country, thereby improving access to critical treatments.

Denosumab Biosimilars are biosimilar versions of the original Denosumab drug, which is used for the treatment of various medical conditions, including osteoporosis and bone-related disorders. By manufacturing and marketing these biosimilars, The Searle Company Limited aims to address the growing demand for these medicines in Pakistan and ensure their availability to a wider patient population.

This collaboration signifies The Searle Company Limited’s commitment to expanding its portfolio of products and businesses, with a focus on enhancing the quality of earnings and shareholder value. By entering the biosimilars market, the company is poised to capitalize on the increasing demand for cost-effective and high-quality biological medicines in Pakistan.

The post The Searle Company Limited Collaborates with Mabwell Pharmaceuticals to Manufacture and Market Denosumab Biosimilars in Pakistan appeared first on Pakistan Company News.